Riprazo

RSS
Withdrawn

This medicine's authorisation has been withdrawn

aliskiren
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 22 August 2007, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Riprazo, (aliskiren), which had been approved for treatment of essential hypertension. The marketing authorisation holder (MAH) responsible for Riprazo was Novartis Europharm Ltd. 

On 24 January 2013, the European Commission issued a decision to withdraw the marketing authorisation for Riprazo, following its receipt of a letter dated 18 December 2012 notifying the Commission of the MAH’s decision to voluntarily withdraw the marketing authorisation for this product for commercial reasons. Riprazo was marketed in the following European countries: Spain (until 31 December 2012) and was not marketed in any other European country. 

Pursuant to this decision, the European public assessment report for Riprazo is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (267.39 KB - PDF)

View

español (ES) (188.34 KB - PDF)

View

čeština (CS) (236.86 KB - PDF)

View

dansk (DA) (188.88 KB - PDF)

View

Deutsch (DE) (250.26 KB - PDF)

View

eesti keel (ET) (187.97 KB - PDF)

View

ελληνικά (EL) (275.64 KB - PDF)

View

français (FR) (250.06 KB - PDF)

View

italiano (IT) (192.22 KB - PDF)

View

latviešu valoda (LV) (242.57 KB - PDF)

View

lietuvių kalba (LT) (217.51 KB - PDF)

View

magyar (HU) (229.63 KB - PDF)

View

Malti (MT) (235.53 KB - PDF)

View

Nederlands (NL) (188.74 KB - PDF)

View

polski (PL) (297.59 KB - PDF)

View

português (PT) (264.01 KB - PDF)

View

română (RO) (218.03 KB - PDF)

View

slovenčina (SK) (278.35 KB - PDF)

View

slovenščina (SL) (228.45 KB - PDF)

View

Suomi (FI) (265.85 KB - PDF)

View

svenska (SV) (249.95 KB - PDF)

View

Product information

български (BG) (902.17 KB - PDF)

View

español (ES) (619.59 KB - PDF)

View

čeština (CS) (789.29 KB - PDF)

View

dansk (DA) (637.46 KB - PDF)

View

Deutsch (DE) (669.55 KB - PDF)

View

eesti keel (ET) (654.53 KB - PDF)

View

ελληνικά (EL) (996.88 KB - PDF)

View

français (FR) (745.35 KB - PDF)

View

íslenska (IS) (675.49 KB - PDF)

View

italiano (IT) (757.31 KB - PDF)

View

latviešu valoda (LV) (810.27 KB - PDF)

View

lietuvių kalba (LT) (759.46 KB - PDF)

View

magyar (HU) (791.1 KB - PDF)

View

Malti (MT) (907.63 KB - PDF)

View

Nederlands (NL) (621.18 KB - PDF)

View

norsk (NO) (659.16 KB - PDF)

View

polski (PL) (843.1 KB - PDF)

View

português (PT) (721.42 KB - PDF)

View

română (RO) (689.67 KB - PDF)

View

slovenčina (SK) (835.24 KB - PDF)

View

slovenščina (SL) (788.82 KB - PDF)

View

Suomi (FI) (636.53 KB - PDF)

View

svenska (SV) (606.45 KB - PDF)

View
Latest procedure affecting product information: IG/0209/G
17/08/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (248.08 KB - PDF)

View

español (ES) (226.23 KB - PDF)

View

čeština (CS) (233.81 KB - PDF)

View

dansk (DA) (205.62 KB - PDF)

View

Deutsch (DE) (206.63 KB - PDF)

View

eesti keel (ET) (207.33 KB - PDF)

View

ελληνικά (EL) (250.29 KB - PDF)

View

français (FR) (209.37 KB - PDF)

View

íslenska (IS) (226.53 KB - PDF)

View

italiano (IT) (226.09 KB - PDF)

View

latviešu valoda (LV) (216.14 KB - PDF)

View

lietuvių kalba (LT) (539.5 KB - PDF)

View

magyar (HU) (241.81 KB - PDF)

View

Malti (MT) (235.35 KB - PDF)

View

Nederlands (NL) (226.03 KB - PDF)

View

norsk (NO) (228.5 KB - PDF)

View

polski (PL) (233.81 KB - PDF)

View

português (PT) (227.59 KB - PDF)

View

română (RO) (228.75 KB - PDF)

View

slovenčina (SK) (235.4 KB - PDF)

View

slovenščina (SL) (233.41 KB - PDF)

View

Suomi (FI) (228.05 KB - PDF)

View

svenska (SV) (227.48 KB - PDF)

View

Product details

Name of medicine
Riprazo
Active substance
aliskiren
International non-proprietary name (INN) or common name
aliskiren
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09XA02

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Authorisation details

EMA product number
EMEA/H/C/000853
Marketing authorisation holder
Novartis Europharm Ltd.

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Marketing authorisation issued
22/08/2007
Withdrawal of marketing authorisation
24/01/2013
Revision
8

Assessment history

This page was last updated on

Share this page